Slingshot members are tracking this event:
Bristol-Myers Squibb Announces Opdivo did not meet trial primary endpoint of progression-free survival in patients expressing PD-L1 = 5%
Slingshot Insights Explained
Aug 05, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Opdivo, Nivolumab, Advanced Non-small Cell Lung Cancer, Checkmate 026